Benralizumab (anti-IL-5Rα) FDA-approved for CRSwNP (2024)

OSTRO trial led to FDA approval of benralizumab for CRSwNP in 2024, making it the fourth approved biologic. Unique ADCC mechanism achieves near-complete eosinophil depletion.